



www.genfit.com

GENFIT: MINUTES OF THE COMBINED SHAREHOLDERS' MEETING OF JUNE 26, 2013

■ The large majority of shareholders adopted the totality of resolutions proposed by the Management Board

Lille (France), Boston (Massachusetts, United States), June 19, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that its share holders have voted in favor of the totality of the resolutions proposed by the Management Board during the Combined Shareholders' Meeting that was held in Lille on June 26, 2013.

The shareholders approved all the resolutions proposed by the Management Board by a large majority of at least 92% of the cast votes.

In particular, the shareholders approved the corporate and consolidated financial statements for the 2012 financial year.

During this combined shareholders' meeting, the Management Board notably stated that:

- the cash position of the company amounts to approximately € 30 million as of the end of June 2013, as compared to € 6.3 million on December 31st, 2012,
- GFT505 continues its development according to plan. In October the company will report on the intermediate clinical results which should confirm the safety of use of the product in the context of the phase IIb study in NASH,
- the company aims to maintain partnerships with the pharmaceutical industry at the heart of its strategy,
- the company will not execute the 8th tranche of the convertible loan into shares that was contracted in December 2012,
- the delegation accorded by the general assembly for the raising of capital with the terms of preferential subscription rights will only be executed in the case of very favorable market conditions.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board

Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr